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Metabolic syndrome is defined as a cluster of alterations related with insulin resistance 
(obesity, dyslipidemia, hypertension and impaired glucose metabolism),which are 
associated with a higher risk of cardiovascular disease in adults. Several definitions 
have been proposed for older children and adolescents. However, no definitions have 
been made according to pubertal status, and those in prepubertal state have not received 
attention enough, despite there are data suggesting the early presence of risk factors. 
The new insights concerning healthy and unhealthy metabolic status or the addition of 
novel metabolic risk biomarkers, may contribute to the knowledge about the 
development of metabolic syndrome in children.This manuscript reviews the available 
evidence on metabolic syndrome during childhood, focusing on the prepubertal period. 
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Introduction 
Metabolic syndrome (MetS) is defined as a cluster of cardiometabolic risk factors 
(obesity, dyslipidemia, elevated blood pressure and impaired glucose metabolism) 
which are associated with a higher risk of cardiovascular disease (CVD) and type 2 
diabetes mellitus in adults. The pathophysiological basis of MetS is not yet completely 
understood, butcentral obesity and insulin resistance (IR) seem causative factors. There 
are several definitions for adults that share most of the variables, whileusing different 
cut-off values(1). Similarly, there are manydefinitions proposed for children and 
adolescents, but there is no consensus definition yet. These definitions agree on defining 
MetS in older children and adolescents, since puberty is well-known as a critical lapse 
for IR(2). However, the diagnosis of MetS in prepubertal children is still an uncertain 
concept.Some limitations arerelated with the unavailability ofpopulation-specific cut-off 
points for the variables used in the definition, which should beestablished with control 
groups with the same characteristics of ethnicity, age, sex, and pubertal stage, and also 
withthe absence of longitudinal studies. 
 During puberty,physiological insulin resistance takes place, however, there are 
data thatsuggestan increase of metabolic risk if obesityexists, although the transition 
from middle to late puberty seems to reverse it(3).The clinical utility of the diagnosis of 
MetS in childhood lies in the recognition of those subjects with the highest risk of 
developing CVD, at short and /or long term. Strategies to prevent or treat MetSonly 
make sense if the diagnosis remains stable during the transition from childhood to 
adolescence. This follow-up has been studied mainly from adolescence to adulthood, 
showing contradictory results. In this context, there is little evidence on how 
cardiometabolic risk factors or MetS change during the transition from the prepubertal 
stage to older ages. 
 
Definition of metabolic syndrome in children 
More than 40 different MetSdefinitions have been published for children and 
adolescents(4).Most of them were based on the National Cholesterol Educational 
Program (NCEP) definition for adolescents aged 12 to 19 years (Table 1). This 
definition is based on the fulfillment of3 out of 5 risk factors:waist circumference 
(WC)≥90th percentile (age and sex specific), fasting plasma triglycerides (TG)≥ 
110mg/dL, high density lipoprotein-cholesterol (HDL-c)≤ 40 mg/dL, fasting plasma 
glucose (FPG)≥ 110 mg/dL and blood pressure (BP)≥ 90th percentile (age and sex 
specific)(5). 
In 2007, the International Diabetes Federation (IDF) proposed a specific 
definition for children and adolescents, recognizing that MetS parameters change with 
age and pubertal development. Itincludedchildren over 10 years, arguing MetS cannot 
be diagnosed as an entity in younger children, although those with obesity should be 
encouraged to lose weight in order to prevent the development of IR or other 
complications(6). They established the same criteria and cut-off points used for adults. 
Since then, most authors investigatingMetS, unifiedchildren and adolescents with 
different pubertal stages, using the same criteria (usually, IDF- and NCEP-adapted or 
modified definitions coming from adults) for all individuals, despite none of these 
definitions were especially made according pubertal status (table 1). 
The differences between these definitions arebased on their specific thresholds, 
which are usually expressed as percentiles for each component, generally based 
onpopulation-specific reference values. On one hand, variations are due to sex and age 
(or even height or ethnicity), anthropometry (body mass index or waist circumference), 
as well as metabolic (lipids and glucose/insulin metabolism) and cardiovascular (blood 
pressure) parameters.On the other hand, pubertyhas been shown to influence the 
mentioned components, being a crucial period for IR, and therefore, for cardiovascular 
risk factors and the development of MetS(7).In fact, IR promotes afast pancreatic beta 
cell deteriorationin adolescents with a pre-diabetes status, whoreacha type 2 diabetes 
earlier than adults(8).However,there are not always age- andsex-specific reference 
values for some of these parameters in children, nor particular considerations for MetS 
diagnosis according pubertal status,despitethere are well-known differences 
incardiometabolic risk factors andMetS diagnosis along the pubertal stages(3,7,9).  
The above-mentioned NCEP and IDF adapted definitions were made for older 
children and adolescents, with ages probably included during the peri- and post-pubertal 
periods. In this context, the IDEFICS study proposed a new definition of MetS in early 
childhood (most of them in prepubertal stage), with age- and sex-specific values for 
each risk factor, based on 18745 European children aged 2-10.9 years(10). This 
definition still requires forthe fulfillmentof at least 3 out of 5 risk factors,establishing 
different levels of monitoring for these children in relation to the risk of disease. 
 
Continuous MetS score and metabolic status 
However, this original MetS construct has been questionedfor severalreasons. On one 
hand, the fulfillmentof each MetScriteria is dichotomous (yes/no), whiletheirvariables 
are continuous. Some authors have proposed the diagnosis of MetS as a continuum, 
arguing the traditional definition wasno sensitive enough(11). A MetS score,built by 
addingthe different z-scores of each risk factor,allows to measuremetabolic risk (higher 
z-scores imply higher metabolic risk).However, the MetS score also presents some 
limitations. First, there is no unified statistical method for calculating this score (z-
scores, factor analysis, principalcomponents analysis and confirmatory factor analysis 
have been reported). Second, these methods are sample-specific and, therefore, MetS 
scores cannot be compared between studies unless demographic characteristics, 
distribution of data, and measures of central tendency and variability were similar 
between samples(11,12). In this context, Vukovicet al.(13)haveproposed a new MetS 
score that simplifies previous statistical methods. It wascalled “Pediatric siMS” based 
on the definition by Soldatovicet al.(14)for adult population, although itusedthe IDF 
definition of MetS for children (over 10 years). The validity of these various methods 
for predicting MetS in children have been reported to be high and similar between 
them(12).  
 On the other hand, the distinction between metabolically healthy(MHO) or 
unhealthy (MUO) children withobesityis particularly focused on those children who 
display a healthy cardiometabolic profile without other MetSassociated factors 
(15).Given the lack of consensus on the MH definition during the past years,the 
assessment and interpretation of cardiometabolic risk has beenchallenging and 
complicated by the large number of definitions.Recently, Damanhouryet al.(16)have 
proposed a consensus definition of MH obesity which needsthe accomplishment of all 
these criteria:BMI-SDS >+2 SD (according tothe WHO growth charts), HDL-c> 40 
mg/dL(or > 1.03 mmol/l), TG ≤ 150 mg/dL(or ≤ 1.7 mmol/l), SBP and DBP ≤ 90th 
percentile, and a measurement of glycemia. However, the authors did not reacha 
consensus regardingthe measurement of glycemia nor itscut-off value, and the pubertal 
status was not considered either.  
Based on these issues, the American Academy of Pediatrics has recently 
recommended to focus on metabolic and cardiovascular risk factors independently, 
instead of defining MetS in children (17). Thus, beyond the definition used, population-
reference values (age- and sex-specific) for each MetScomponent have been 
increasingly reported to aid in the identification of these cardiometabolic risk factors in 
prepubertal children(18–22). 
 
Cardiometabolic risk factors in prepubertal children 
There is evidence ofthe existence of cardiometabolic risk factors in peri- and post-
pubertal children(23), but less efforts have been made on finding out if these alterations 
are already present at prepubertal stage. Unfortunately, the pubertal status is not always 
specified in studies with younger children, which usually onlyreport age ranges,limiting 
the extent of the conclusions for theprepubertalpopulation. However, there are 
severalreports suggesting the early existence of these cardiometabolic risk factors 
during theprepubertalperiod(9,24,25).  
The use of the variousdefinitions of MetS, and of those referring to MH or MU 
status, brings back wide differences in the estimated prevalence of cardiometabolic risk 
factors in prepubertal children. Most recent studies applying different definitions in 
their samples, show a significant variability in this prevalence(10,24,26). Olzaet 
al.(24)usedseven different definitions of MetS for children and adolescents ona sample 
of478 prepubertal childrenwithobesity, andfound a prevalence of MetS ranging from 
8.3% to 34.2% depending on the definition (5,6,27–31).  
The prevalence of MetS found by the IDEFICS definition among12.319 children 
(mostly prepubertal), 951 of which had obesity, was higher than with 
others(5,6,30),with the lowest one found for the IDF definition (0.4% for total 
population)(10). In contrast to previous definitions, they found that the proportion of 
children exceeding the cut-off of each component was similar, with no component 
showing a lower prevalence. Dyslipidemia and increased WC were the components 
found to have the higher likelihood to classify a child as with MetS according to the 
other compared definitions. 
In another study with 622 prepubertal children with obesity(5-10.9 years), the 
prevalence of MUO (defined as: obesity and at least one another metabolic risk criteria 
of each definition) varied from 14 to 70%, using eight differentclassifications(26). Five 
definitions were based on classical MetS components(3,6,10,24,32) and three 
includedhomeostatic model assessment- IR (HOMA-IR) cut-offs(24,32,33). Those of 
Olzaet al(24). and Ahrenset al.(10) showed the highest prevalence, and IDF(6) and 
those based on HOMA-IR the lowest ones.  
There is a recent study that analyzes cardiometabolic risk factors in 1409 
childrenwith obesity (mean 9.7 (2.2-17.9) years) and classified them according to 
pubertal status and age in four groups (Group 1, prepubertal< 6 years; Group 2, 
prepubertal>6 years; Group 3, pubertal stages II-III; Group 4, pubertal, stages IV-IV). 
They reported a prevalence of MHO (defined as obesity without any other risk factor: 
BP, glycemia, insulinemia, glycemia and insulinemia after an oral glucose tolerance test 
(OGTT), HOMA-IR, total cholesterol, HDL-c, LDL-c and TG) of 59.8% for group 1, 
and nearly 30% on the other three groups. For groups 1 and 2, the prevalence of the 
followingcardiometabolic risk factors were, respectively: hypertension in 5.9 and 
12.9%, abnormal HOMA-IR in 19.8% and 49,9%, or dyslipidemia in 20.6 and 
36.1%(9). In conclusion, it seems that cardiometabolic risk factors are present in 
prepubertal children regardless of the definition (MetS, MH or MU status) used (Table 
1).  
 
Other non-traditional cardiometabolic risk factors 
Some other cardiovascular and metabolic biomarkers associated with higher 
cardiometabolic risk,both in adults and children(1), are not included in the 
MetStraditional framework,although they couldhelp modulate the diagnosis.These 
parameters have been reported to be involved in the IR state or the proinflammatory 
status, at the first steps ofMetSdevelopment. 
The adipose tissue constitutes anendocrine organ that secretes several factors, as 
proinflammatory cytokines (e.g. tumor necrosis factor-alfa andinterleukins) and 
adipokines (e.g. adiponectin and leptin), that are related to the cardiometabolic risk 
profile(1). Plasma leptin concentrations have been found to be increased in prepubertal 
children with IR(34), and associated with high BMI and fat mass, as well as withother 
MetS factors and continuous MetSscores(25,26,35). Conversely, adiponectinplasma 
levels seem to be low in prepubertalchildren withoverweight/obesity compared with 
those with normal-weight (26,35–37). The leptin/adiponectin ratio has been also studied 
as a cardiometabolic risk marker, and foundhigherin those prepubertal children with 
higher BMI and BMI z-scores, and with other MetSfactors(35). Other adipokines such 
asresistin, irisin,vifastin,retinol-binding protein 4orS100A4proteinhavealsobeen 
foundtobe associatedwithcardiometabolic risk in prepubertal children(26,36–42). For all 
of these new factors, despite the attempts of stablishing a unique cut-off value, the use 
of age- and sex-specific values and its percentiles should be more appropriate(43,44), as 
those reported for classical cardiometabolic risk factors(10). 
The effect of metabolic impairment has also been observed through several 
biomarkers that reflect the low-grade inflammatory status (C-reactive protein, TNF-alfa, 
IL-6, IL-8), vascular damage (sE-selectin, sICAM-1, sVCAM-1) and risk of CVD 
(Active-PAI-1, PAI-1, mieloperoxidase), both in children(25,26,36,37)and adults(1). 
The circulating concentration of these moleculeshave been found to be higher in 
prepubertal children with higher BMI(36,37), higher waist-to-height ratio(37), higher 
scores of continuous MetS(25) and MU status(26).  
The apolipoproteins have been studied as markers of dyslipidemia and predictors 
of atherosclerosis in adults. The apo A1 is an anti-atherogenic particle, which is the 
main protein of HDL. In turn, the apo B is a pro-atherogenic particle included in several 
lipid fractions such asLDL. The ratio apo B/A1 represents the lipid profile and has been 
shown to be consistently higher in prepubertalchildren with higher metabolic risk (with 
a positive correlation with the number of MetS factors) and to be positively associated 
with BMI(45,46). Moreover, apo B levels seemed to track better than other markers of 
dyslipidemia in the transition from childhood to adolescence, showing the importance 
of its determination in children for the prediction of future cardiovascular risk (47).  
Another consequence of the mentioned metabolic derangement isthe non-
alcoholic fatty liver disease (NAFLD), as the hepatic manifestation of an IR state and 
the most common cause of chronic hepatic disease in childhood. In this context, alanine 
aminotransferase (ALT), previously related to IR and NAFLD in adults with MetS(48), 
has beenfound increasedin obese prepubertal children compared with their normal-
weight peers, and positively correlated with MetS and impaired insulin sensitivity 
(HOMA-IR > 97.5thpercentile)(49).Fetuin-A, an hepatokine related to hepatic insulin 
function, has been also associated with IRand other metabolic risk factors (z-scores 
BMI, blood pressure and dyslipidemia) in prepubertal children(50). Other biomarkers 
such as vifastin, cytokeratin 18 or pentraxin-3 have been proposedforthe non-
invasiveassessment of NAFLD in children(41,51,52).  
Last, elevated levels of serum uric acid have also beenassociated withhigher 
BMI and other MetS factors (higher blood pressure and TG, and low HDL-c), as well as 
withIR, markers of endothelial damage, and carotid intima-media thickness in 
prepubertal children(53–55).  
To study these non-classical risk factors may beuseful to demonstrate the 
presence of cardiometabolic derangements and to improve the ability to diagnose 
subjects with a worse metabolic profileand a higher risk of CVD.However, nowadays 
most of them are exclusively investigated for researchpurposes. 
 
Conclusion 
The consensus definition of MetS in pediatric population has not been reached yet, but 
recently proposals may improve the diagnosis of MetS, especially in prepubertal 
children. The application of continuous MetS scores or the measurement of 
novelbiomarkers may also contribute to determine the cardiometabolic risk of children 
in both research and clinical settings. Beyond the chosen definition, it could be adequate 
for future studies to focus on the grouping of cardiometabolic risk factors, without 
trying to defineMetS in children. Despite the debate regarding the stability of the MetS 
construct from childhood to adolescence, there is enough evidence ofthe influence of 
individual risk factors onits development, especially obesity, on the risk of future CVD. 
Hence, longitudinal studies and strategies for fighting against themfrom the beginning 
of childhood should be continued.  
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Table 1.Authors’ Criteria used for the diagnosis of metabolic syndrome in prepubertalchildren.  
Study Population Obesity Blood pressure Lipids Glucose/Insulin 
Cook et al. 2003(5) White, black and 
Mexican-American 
12-19 years 
Male and female 
WC ≥90th P 
 
SBP or DBP ≥90thP TG ≥110 mg/dL 
HDL-c ≤40 mg/dL 
FBG ≥110 mg/dL 





Male and female 
WC ≥75th P 
 
SBP ≥90thP TG ≥110 mg/dL 
HDL-c ≤40 mg/dL 
FBG ≥110 mg/dL 
Weiss et al. 
(2004)(28) 
White, Black and 
Hispanic 
4-20 years 
Male and female 
BMI >97thP  
or z-score >2 
SBP or DBP ≥95thP TG ≥95th P and  
HDL-c ≤5thP for age, sex and 
race 
OGTT >140 and 
<200 mg/dl at 2h 




American, or mixed) 
8-13 years 
Male and female 
WC ≥90thP SBP or DBP ≥90thP TG ≥90th P and  
HDL-c ≤10thP for age, sex 
and race 
OGTT at 120 
min≥140 and <200 
mg/dl 
Viner et White, Black, South BMI ≥95th P SBP ≥95thP Any of the following: Fasting 
al.(2005)(30) Asian, and other or 
mixed ethnicity 
2-18 years 
Male and female 
 TG≥150 mg/dl, HDL-c 





(stages 2–4) ≥30 
mU/l andpost-
pubertal ≥20 
mU/l), FBG ≥110 
mg/dl or 
OGGT 
at 120 min ≥140 
mg/dl 
Ford et al. 
(2005)(31) 
12-17 years 
Male and female 
WC ≥90thP 
 
SBP or DBP ≥90thP TG ≥110 mg/dL 
HDL-c ≤ 40 mg/dL 
FBG ≥100 mg/dL 
Zimmetet al. 
(2007)(6) 
≥10 to≤16 years WC ≥90thP SBP ≥130 or  
DBP ≥85mmHg 
TG ≥150 mg/dL 
HDL-c <40 mg/dL 
FBG ≥100 mg/dL 




WC ≥90th P SBP or DBP ≥90thP TG ≥90thP or  
HDL-c ≤10thP 
HOMA-IR or FBG 
≥90thP 




WHtR≥0.5 SBP or DBP ≥90thP TG ≥110 mg/dL 
HDL-c ≤ 40 mg/dL 
FBG ≥110 mg/dL 
Table modified from Olzaet al.(24). 
BMI: Body mass index; DBP: diastolic blood pressure; FBG: Fasting blood glucose; HDL-c: High density lipoprotein-cholesterol; HOMA-IR: 
homeostasis model assessment of insulin resistance; LDL-c: Low density lipoprotein-cholesterol; OGTT: Oral glucose tolerance test; SBP: 
systolic blood pressure; WC: Waist circumference; WHtR: waist-to-height ratio; TG: Tryglycerides.  
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